Please login to the form below

Not currently logged in
Email:
Password:

Zafgen

This page shows the latest Zafgen news and features for those working in and with pharma, biotech and healthcare.

Second patient death in Zafgen's obesity drug trial

A second patient enrolled in a phase III trial of Zafgen's obesity drug candidate beloranib has died, placing the future of the programme in doubt. ... Thomas Hughes, Zafgen's chief executive, said: "Our thoughts are with the patient and their family at

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics